Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: Another feature of the atherogenic dysmetabolism

Metabolism: Clinical and Experimental

Volumn 58, Issue 5, 2009, Pages 661-667

  Rogowski, Ori ^a,b   Shapira, Itzhak ^a,b   Steinvil, Arie ^a,b   Berliner, Shlomo ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; ISRAEL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 64349083817     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.01.005     Document Type: Article

References (33)

1. Lemieux I., Pascot A., Couillard C., Lamarche B., Tchernof A., Almeras N., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 102 (2000) 179-184
2. LaMonte M.J., Ainsworth B.E., DuBose K.D., Grandjean P.W., Davis P.G., Yanowitz F.G., et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis 171 (2003) 123-130
3. St-Pierre J., Lemieux I., Perron P., Brisson D., Santure M., Vohl M.C., et al. Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol 99 (2007) 369-373
4. Gazi I.F., Filippatos T.D., Tsimihodimos V., Saougos V.G., Liberopoulos E.N., et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 41 (2006) 647-654
5. Rogowski O., Shapira I., Ben Asayag E., Bornstein N.M., Toker S., Melamed S., et al. Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagul Fibrinolysis 17 (2006) 19-22
6. Rogowski O., Shapira I., Peretz H., and Berliner S. Glycohaemoglobin as a determinant of increased fibrinogen concentrations and low-grade inflammation in apparently healthy nondiabetic individuals. Clin Endocrinol (Oxf) 68 (2008) 182-189
7. Zeltser D., Rogowski O., Mardi T., Justo D., Tolshinsky T., Goldin E., et al. Clinical and laboratory characteristics of patients with atherothrombotic risk factors presenting with low concentrations of highly sensitive C-reactive protein. Atherosclerosis 176 (2004) 297-301
8. Zeltser D., Rogowski O., Berliner S., Mardi T., Justo D., Serov J., et al. Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and apparently health people. Heart 90 (2004) 277-281
9. Rogowski O., Toker S., Shapira I., Melamed S., Shirom A., Zeltser D., et al. Values of high sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 95 (2005) 152-155
10. Berliner S., Rogowski O., Aharonov S., Mardi T., Tolshinsky T., Rozenblat M., et al. Erythrocyte adhesiveness/aggregation. A novel biomarker for the detection of low grade internal inflammation in individuals with atherothrombotic risk factors and proven. vascular disease. Am Heart J 149 (2005) 260-267
11. Rogowski O., Shapira I., Shirom A., Melamed S., Toker S., and Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 93 (2007) 940-947
12. Rifai N., Tracy R.P., and Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45 (1999) 2136-2141
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
14. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
15. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
16. Despre's J.P., Lemieux L., Bergeron J., Pibarot P., Mathieu P., Larose E., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28 (2008) 1039-1049
17. Blackburn P., Lemieux I., Lamarche B., Bergeron J., Perron P., Tremblay G., et al. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically assessed coronary artery disease in women. Diabetes Care 31 (2008) 170-172
18. Sabatine M.S., Morrow D.A., Jablonski K.A., Rice M.M., Warnica J.W., Domanski M.J., et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 115 (2007) 1528-1536
19. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. [published erratum appears in N Engl J Med 1997 Jul 31;337(5):356] [see comments]. N Engl J Med 336 (1997) 973-979
20. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
21. Koenig W., Lowel H., Baumert J., and Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation 109 (2004) 1349-1353
22. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
23. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440 (2006) 1217-1221
24. Danenberg H.D., Szalai A.J., Swaminathan R.V., Peng L., Chen Z., Seifert P., et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108 (2003) 512-515
25. Ridker P.M., Wilson P.W.F., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
26. Kelishadi R., Sharifi M., Khosravi A., and Adeli K. Relationship between C-reactive protein and atherosclerotic risk factors and oxidative stress markers among young persons 10-18 years old. Clin Chem 53 (2007) 456-464
27. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
28. Esmaillzadeh A., Mirmiran P., Azadbakht L., and Azizi F. Prevalence of the hypertriglyceridemic waist phenotype in Iranian adolescents. Am J Prev Med 30 (2006) 52-58
29. Esmaillzadeh A., Mirmiran P., and Azizi F. Whole-grain intake and the prevalence of hypertriglyceridemic waist phenotype in Tehranian adults. Am J Clin Nutr 81 (2005) 55-63
30. Rogowski O., Shapira I., and Berliner S. Exploring the usefulness of inflammation-sensitive biomarkers to reveal potential sex differences in relation to low-grade inflammation in individuals with the metabolic syndrome. Metabolism 57 (2008) 1221-1226
31. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49 (2007) 2129-2138
32. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
33. Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, et al. Metabolic syndrome, inflammation, and the incident heart failure in the elderly: the Cardiovascular Health Study. Circulation: heart failure. Published online before print, September 23, 2008.